TICKERNERD
Menu
ANIPANIPHealthcare · Drug Manufacturers - Specialty & Generic

ANIP Stock Forecast: ANI Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$72
−1.46% on the day

The 9 Wall Street analysts covering ANI Pharmaceuticals, Inc. hold a median 12-month price target of $104 — +45.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.7B
Ticker Nerd rank
93 / 100
Median analyst target
$104
Analysts covering
9
Revenue$266.0M+25.9% y/y
Operating income$39.8M
Net income$24.7M
Free cash flow$53.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.5%
1M
+0.4%
YTD
−9.4%
1Y
−22.3%
From 52W high
−25.0%
From 52W low
+1.9%
$70
$95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANIP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ANI Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Volatility
96
Growth
94
Quality
91
Accruals
69
Issuance
67
Revisions
52
Momentum
42
Size
38

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (42): The shares have been drifting down relative to others.

Size (38): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANIP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANIP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$70$80$90$100$110$120Jan 26Apr 26Jul 26Oct 26ANIPHigh $121Median $104Low $85

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
7 Buy2 Hold0 Sell
Low $85Median $104High $121

The green dot is the last close — the median target sits +45.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Sept 2026OppenheimerInitiatesPerform$85
10 Aug 2026Canaccord GenuityMaintainsHold$91 → $90
10 Aug 2026Canaccord GenuityMaintainsHold—
10 Aug 2026GuggenheimMaintainsBuy$124 → $119
10 Aug 2026GuggenheimMaintainsBuy—
17 July 2026Canaccord GenuityInitiatesHold$91
17 July 2026Canaccord GenuityInitiatesHold—
10 July 2026GuggenheimReiteratesBuy$124
10 July 2026GuggenheimReiteratesBuy—
16 Jan 2026GuggenheimMaintainsBuy—
9 Dec 2025BarclaysInitiatesOverweight—
10 Nov 2025GuggenheimMaintainsBuy—
9 Oct 2025Truist SecuritiesMaintainsHold—
24 Sept 2025JP MorganMaintainsOverweight—
17 Sept 2025HC Wainwright & Co.MaintainsBuy—
8 Sept 2025GuggenheimMaintainsBuy—
11 Aug 2025Truist SecuritiesMaintainsHold—
8 Aug 2025HC Wainwright & Co.MaintainsBuy—
10 July 2025HC Wainwright & Co.InitiatesBuy—
12 May 2025GuggenheimReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANIP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ANIP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, ANI Pharmaceuticals, Inc. returned −22.3% against +17.3% for the S&P 500, dividends included.

ANIP vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26ANIPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANIP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1.0%
Analysts raising
2
Analysts cutting
2
Fundamentals

ANI Pharmaceuticals, Inc. (ANIP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
15.6×

Cheaper than 44% of US stocks

Price / sales
1.7×

Cheaper than 56% of US stocks

Price / book
2.6×

Cheaper than 36% of US stocks

EV / EBITDA
8.6×

Cheaper than 42% of US stocks

Growth & margins
Revenue growth (YoY)
25.9%

Higher than 75% of US stocks

Earnings growth (YoY)
189.1%

Higher than 90% of US stocks

Gross margin
62.4%

Higher than 76% of US stocks

Operating margin
15.0%

Higher than 72% of US stocks

Net margin
11.1%

Higher than 72% of US stocks

Returns & dividend
Return on equity
20.5%

Higher than 81% of US stocks

Return on assets
5.4%

Higher than 79% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ANI Pharmaceuticals, Inc. (ANIP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ANI Pharmaceuticals, Inc. has a market value of $1.7B and an enterprise value of $1.8B.

  • Revenue in the twelve months to 30 June 2026: $978.4M. The latest quarter grew 25.9% year on year.

  • Net income over the same four quarters: $108.3M, a 11.1% net margin.

  • Diluted earnings per share, trailing twelve months: $4.64.

  • Free cash flow in the twelve months to 30 June 2026: $167.5M.

  • ANI Pharmaceuticals, Inc. spent $344K on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 23.0M.

  • Trailing P/E: 15.6×; forward P/E: 6.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • ANI Pharmaceuticals, Inc. employs 970 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

ANIP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ANIPANI Pharmaceuticals, Inc.$1.7B
93
ETONEton Pharmaceuticals, Inc.$1.6B
99
PAHCPhibro Animal Health Corp.$1.5B
91
XERSXeris Biopharma Holdings, Inc.$1.8B
83
PRGOPerrigo Co. Plc$1.9B
77
BCRXBioCryst Pharmaceuticals, Inc.$2.0B
88
TRLVTrulieve Cannabis Corp.$2.0B
89

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ANI Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANIP news & analysis

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

GlobeNewsWire · 30 Sept 2026positive

ANI Pharmaceuticals announced that data from its Phase 4 open-label, single-arm SYNCHRONICITY trial for fluocinolone acetonide intravitreal implant will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day at the American Academy of Ophthalmology 2026 Annual Meeting.

Why it matters — A late-breaking oral presentation of Phase 4 trial data highlights the company's clinical progress in the uveitis treatment space and increases visibility of its intravitreal implant program within the ophthalmology community.

Implied Volatility Surging for ANI Pharmaceuticals Stock Options

Zacks Investment Research · 28 Sept 2026neutral

Recent movements in the options market have drawn attention to ANI Pharmaceuticals stock, with implied volatility surging. Zacks Investment Research notes that investors need to closely monitor ANIP based on this options activity.

Why it matters — A surge in implied volatility for ANIP options signals heightened market attention and potential price swings that could be of interest to those following the stock.

ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build

Seeking Alpha · 24 Sept 2026neutral

ANI Pharmaceuticals cut its Cortrophin guidance by roughly $30 million but said second-half expectations remain intact, with fourth-quarter growth depending on gout salesforce productivity. Generics are generating strong cash flow that funds the rare-disease expansion, which is projected to comprise nearly 60% of 2026 revenue.

Why it matters — For ANIP watchers, this signals near-term Cortrophin performance depends on gout salesforce execution while generics cash flow backs the company's shift toward its rare-disease franchise.

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

GlobeNewsWire · 23 Sept 2026positive

ANI Pharmaceuticals announced that it received final FDA approval for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension in 2mg, 3mg, and 5mg strengths. The product is the generic version of the reference listed drug Afinitor Disperz.

Why it matters — This FDA approval expands ANI's generic product portfolio with a new oncology-related offering, potentially broadening its commercial opportunities.

ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

ANI Pharmaceuticals, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with the event transcript published by Seeking Alpha. The presentation gave investors an opportunity to hear the company's management discuss its business at a major industry conference.

Why it matters — ANIP watchers would care because conference presentations offer direct insight into the company's strategy and positioning as communicated by its management team at a prominent healthcare investor event.

FAQ

Frequently asked questions about ANIP stock

What is the ANIP stock price forecast for 2026-2027?

The 9 Wall Street analysts covering ANI Pharmaceuticals, Inc. have a median 12-month price target of $104, with estimates ranging from $85 to $121. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANIP stock a buy right now?

Of the 9 analysts covering ANI Pharmaceuticals, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ANI Pharmaceuticals, Inc. 93 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANIP?

As at 6 Oct 2026, ANI Pharmaceuticals, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will ANIP stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +45.4% from the last close, and Ticker Nerd's factor model ranks ANI Pharmaceuticals, Inc. 93 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANIP stock forecast for 2030?

No analyst covering ANI Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANIP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $121 over the next 12 months.

How has ANIP stock performed over the past year?

ANI Pharmaceuticals, Inc. returned -22.3% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ANI Pharmaceuticals, Inc. do?

ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes branded, generic, and specialty prescription medicines.

What is the latest news on ANIP?

The most recent item we track (GlobeNewsWire, 30 Sept 2026): "ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting". ANI Pharmaceuticals announced that data from its Phase 4 open-label, single-arm SYNCHRONICITY trial for fluocinolone acetonide intravitreal implant will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day at the American Academy of Ophthalmology 2026 Annual Meeting.

Company

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes branded, generic, and specialty prescription medicines. ANI Pharmaceuticals focuses on three main areas: Rare Disease, Generics, and Established Brands. Its portfolio includes therapies for ophthalmology, rheumatology, nephrology, neurology, and pulmonology, alongside a broad range of generic products and established branded medicines. The company also supports contract manufacturing and pharmaceutical development services, leveraging U.S.-based manufacturing capabilities and expertise in complex formulations such as injectables, softgels, oral solids, liquids, and topical products. ANI Pharmaceuticals serves patients, pharmacies, wholesalers, specialty channels, and other healthcare customers through a diversified commercial model built around prescription pharmaceuticals and niche therapeutic markets.

CEO Mr. Nikhil Lalwani · 970 employees · United States · https://www.anipharmaceuticals.com